Recovery After an Initial Schizophrenia Episode (RAISE 1) is an NIMH research project that seeks to fundamentally change the trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in the earliest stages of illness. RAISE is designed to reduce the likelihood of long-term disability that people with schizophrenia often experience. It aims to help people with the disorder lead productive, independent lives. At the same time, it aims to reduce the financial impact on the public systems often tapped to pay for the care of people with schizophrenia.
NIMH awarded separate contracts to two independent research teams to develop interventions that can be tested in real-world treatment settings and be readily adopted and quickly put into practice should they prove successful. The contract awards were made to the Feinstein Institute for Medical Research (Principal Investigator, John M. Kane, M.D.) in Manhasset, NY, and to the Research Foundation for Mental Hygiene at Columbia University (Principal Investigator, Lisa Dixon M.D.) in New York City.
The team led by Dr. Kane has developed the RAISE Early Treatment Program, a research study which is being conducted in community clinics across the United States. This study is comparing the “NAVIGATE” model for community-based treatment for people with first episode psychosis with customary care. NAVIGATE uses a team-based approach to provide people with individualized psychopharmacology, individual resiliency training, family psychoeducation, and supported employment and/or education. A total of 35 sites in 21 states (including over 400 individuals) participated in the study, with sites randomly assigned to provide either the NAVIGATE program or customary services for a minimum of 2 years. Routine assessments were conducted for at least 2 years to evaluate outcomes across a range of different domains, including symptoms, hospitalizations, school and work functioning, and quality of life.
Co-Investigator: Kim T. Mueser, Ph.D.
Co-Investigator: Jennifer Gottlieb, Ph.D.
Co-Investigator: Susan Gingerich, M.S.W.
This is a multi-site study. Please contact the Center investigator for additional information.
Please see abstracts of selected findings of the RAISE study.
Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Meyer-Kalos PS, Gottlieb JD, Glynn SM, Lynde DW, Pipes R, Kurian BT, Miller AL, Azrin ST, Goldstein AB, Severe JB, Lin H, Sint KJ, John M, Heinssen RK. (2016). Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. American Journal of Psychiatry. 173(4):362-72. doi: 10.1176/appi.ajp.2015.15050632. https://www.ncbi.nlm.nih.gov/pubmed/26481
Mueser KT, Meyer-Kalos PS, Glynn SM, Lynde DW, Robinson DG, Gingerich S, Penn DL, Cather C, Gottlieb JD, Marcy P, Wiseman JL, Potretzke S, Brunette MF, Schooler NR, Addington J, Rosenheck RA, Estroff SE, Kane JM. (2019). Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study. Schizophrenia Research, 204:271-281. doi: 10.1016/j.schres.2018.08.015. https://www.ncbi.nlm.nih.gov/pubmed/30139553
Cather C, Brunette MF, Mueser KT, Babbin SF, Rosenheck R, Correll CU, Kalos-Meyer P. (2018) Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. Psychiatry Research, 268:303-311. doi: 10.1016/j.psychres.2018.06.055. www.ncbi.nlm.nih.gov/pubmed/30086471
Inquiries related to the project should be addressed to:
Kim Mueser, Ph.D.
Boston University, Center for Psychiatric Rehabilitation
940 Commonwealth Avenue West, 2nd Floor
Boston, MA 02215